Abstract: The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said

Abstract: Disclosed are devices, systems and methods for improving the reliability of retrieving information from a memory device. An exemplary method includes obtaining a plurality of cell counts for each of a plurality of read voltages applied to the memory device, each of the plurality of cell counts representing a number of cells having a cell voltage value that is within a voltage band corresponding to the read voltage applied thereto, generating, based on the plurality of cell counts, the plurality of read voltages and a design parameter, a set of estimated parameters, the design parameter being based on one or more properties of the memory device, determining an updated read voltage based on the estimated set of parameters, and applying the updated read voltage to the memory device to retrieve the information from the memory device.

Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: A laundry treating apparatus includes a tub, a drum, a cover defining a detergent inlet, a storage body configured to store the detergent, a barrier partitioning an interior of the storage body into first and second detergent spaces, a storage unit water supply nozzle configured to supply water to the first detergent space, a first body through hole defined at a bottom surface of the storage body, a first discharge pipe, a second discharge pipe, a siphon formation pipe surrounding the first discharge pipe and being configured to flow liquid from the first detergent space to the first body through hole based on a liquid level inside the first detergent space, and a space communication unit configured to flow liquid from the first detergent space to the second detergent space based on liquid not being discharged to an outside of the first detergent space through the first body through hole.

Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Abstract: The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof is combined with a drug, which is not suitable for oral administration, and is administered orally, it exhibits an excellent absorption rate without decreasing the biological activities of the drug. Moreover, the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof can be easily prepared in a few steps, which is very advantageous in terms of mass production.

Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The present disclosure is directed to a display device and a method of controlling the display device. The display device includes a memory that stores at least one first gesture image corresponding to at least one function, a camera that obtains a basic image including user's second gesture image, and a controller that extracts the second gesture image from the basic image and displays at least one third gesture image similar to the extracted second gesture image, wherein the third gesture image is included in the first gesture image stored in the memory. The display device and method of controlling the display device may guide a user to make a correct gesture by displaying a gesture image similar to a gesture made by the user among gesture images stored in a memory.

Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Abstract: An NFC-enabled electronic device and a method for operating the same are discussed. The method according to an embodiment includes performing, by the electronic device, tagging with a first external device to establish communication with the first external device; receiving, by the electronic device, at least one of device information and user information from the first external device through the communication; and transmitting, by the electronic device, a remote control signal to at least one second external device, based on the at least one of the device information and the user information.

Abstract: Data analysis of a food item based on one or more digital images of the food item is disclosed. In one embodiment, the method comprises displaying, on a display unit of the smart device, first and second digital images of a meal, where the first digital image is captured before the second digital image. The method also comprises determining a volume of each food item in the first digital image and a volume of each food item in the second digital image by analyzing the first digital image and the second digital image using a digital image processing technique. The method further comprises generating, on the display unit, an amount of intake for the meal based on a difference between the volume of each food item in the first digital image and the volume of each food item in the second digital image.

Abstract: The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said

Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

Abstract: Disclosed is a central controller, comprising: a microphone; an audio output unit configured to output audible information; a wireless communication unit configured to communicate with an electronic device using wireless signals; an event unit configured to receive event information on an event generated from the electronic device, through the wireless communication unit; and a controller configured to control the audio output unit based on the received event information, such that a guide voice indicating a status of the electronic device is output, wherein once a voice for controlling the electronic device is input to the microphone, the wireless communication unit is controlled such that a control command corresponding to the voice is transmitted to the electronic device.

Abstract: This invention relates to novel 1-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R10 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may be used as medicaments for the treatment of diseases such as type II diabetes.